Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.54 – $2.70
16% from low
Borrow rate
5.48%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $18.1K | $0 | $0 | $0 | $0 | $291.7K | $387.6K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $103.3K | $222.3K |
| Gross profit | $0 | $18.1K | $0 | $0 | $0 | $0 | $188.4K | $165.4K |
| Gross margin | — | 100.0% | — | — | — | — | 64.6% | 42.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$66.6K | −$507.0K | −$23.0K | −$31.5K | −$16.3K | −$21.5K | −$1.4M | −$917.0K |
| EBITDA | −$66.6K | −$507.0K | $148.9K | $174.8K | −$16.3K | −$21.5K | $3.6M | −$1.2M |
| Net income | −$206.3K | −$799.0K | −$221.2K | −$229.8K | −$214.7K | −$220.6K | $838.9K | −$1.6M |
| Net margin | — | -4412.7% | — | — | — | — | 287.6% | -399.9% |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds DUTV.
No tracked institution reports a position in DUTV as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-10-10 | 1-for-100reverse |
No one on the platform has traded DUTV yet.
| $2.9B |
| — |
| KARBFKaro Pharma AB (publ) | $5.25 | +0.00% | $1.5B | — |
| MITPFMithra Pharmaceuticals S.A. | $23.90 | +254.07% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.